LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Wednesday. The company traded as low as $75.61 and last traded at $76.3690, with a volume of 3,366 shares trading hands. The stock had previously closed at $77.01.
Wall Street Analyst Weigh In
LMAT has been the subject of several analyst reports. Wells Fargo & Company lowered their target price on LeMaitre Vascular from $94.00 to $86.00 and set an "equal weight" rating for the company in a research note on Thursday, November 5th. Seaport Research Partners set a $110.00 price objective on LeMaitre Vascular in a research note on Thursday, November 5th. Weiss Ratings cut LeMaitre Vascular from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Friday, October 23rd. Barrington Research downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Wednesday, August 5th. Finally, Wall Street Zen lowered shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Three investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, LeMaitre Vascular presently has an average rating of "Hold" and a consensus price target of $108.25.
Check Out Our Latest Report on LeMaitre Vascular
LeMaitre Vascular Price Performance
The stock has a market capitalization of $1.73 billion, a price-to-earnings ratio of 27.48, a P/E/G ratio of 2.27 and a beta of 0.51. The company has a quick ratio of 12.54, a current ratio of 14.60 and a debt-to-equity ratio of 0.39. The stock has a fifty day moving average of $81.17 and a 200-day moving average of $93.87.
LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $0.65 earnings per share for the quarter, missing analysts' consensus estimates of $0.69 by ($0.04). The company had revenue of $67.97 million for the quarter, compared to analyst estimates of $67.39 million. LeMaitre Vascular had a return on equity of 15.33% and a net margin of 23.51%. The firm's revenue for the quarter was up 11.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.75 EPS. On average, equities research analysts predict that LeMaitre Vascular, Inc. will post 2.83 EPS for the current fiscal year.
LeMaitre Vascular Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Thursday, November 19th will be paid a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 1.3%. The ex-dividend date is Thursday, November 19th. LeMaitre Vascular's dividend payout ratio (DPR) is currently 36.36%.
Institutional Investors Weigh In On LeMaitre Vascular
A number of institutional investors and hedge funds have recently bought and sold shares of LMAT. Sterling Capital Management LLC grew its holdings in shares of LeMaitre Vascular by 844.2% during the third quarter. Sterling Capital Management LLC now owns 727 shares of the medical instruments supplier's stock worth $60,000 after purchasing an additional 650 shares during the last quarter. Nykredit A S purchased a new stake in shares of LeMaitre Vascular in the 2nd quarter valued at about $82,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of LeMaitre Vascular in the 2nd quarter valued at about $102,000. EverSource Wealth Advisors LLC boosted its position in shares of LeMaitre Vascular by 28.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,393 shares of the medical instruments supplier's stock valued at $152,000 after purchasing an additional 308 shares during the period. Finally, Teton Advisors LLC acquired a new stake in shares of LeMaitre Vascular in the 1st quarter valued at about $218,000. 84.64% of the stock is owned by hedge funds and other institutional investors.
About LeMaitre Vascular
(
Get Free Report)
LeMaitre Vascular develops, manufactures and markets medical devices used primarily in the treatment of vascular disease. Its products support procedures performed by vascular surgeons and include vascular grafts, embolectomy catheters, carotid shunts, valvulotomes and other instruments used in vascular surgery. Founded in 1983 by vascular surgeon George LeMaitre, the company is headquartered in Burlington, Massachusetts. Its products are sold to hospitals and medical professionals around the world through a combination of direct sales and distributors.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider LeMaitre Vascular, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LeMaitre Vascular wasn't on the list.
While LeMaitre Vascular currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.